MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.4x | −0.8x | −0.5x | |
PEG Ratio | 0.30 | 0.10 | 0.00 | |
Price/Book | 9.0x | 1.3x | 2.6x | |
Price / LTM Sales | 9.1x | 1.5x | 3.2x | |
Upside (Analyst Target) | 82.6% | 155.6% | 38.8% | |
Fair Value Upside | Unlock | 25.7% | 5.4% | Unlock |